Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$2.3B
59M shares
52-week range
$22.24 – $46.00
63% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $94.4M | $117.9M | $0 | $0 | $14.2M | $26.8M | $36.5M | $54.0M |
| Cost of revenue | $1.4M | $1.3M | $18.8M | $18.8M | $1.7M | $9.5M | $4.2M | $11.5M |
| Gross profit | $93.0M | $116.6M | −$18.8M | −$18.8M | $12.5M | $17.3M | $32.3M | $42.5M |
| Gross margin | 98.5% | 98.9% | — | — | 88.0% | 64.6% | 88.6% | 78.7% |
| R&D | $341.3M | $410.9M | $211.0M | $257.0M | $279.9M | $288.9M | $301.3M | $334.4M |
| Operating income | −$362.5M | −$426.3M | −$335.9M | −$378.4M | −$389.0M | −$391.5M | −$425.7M | −$472.1M |
| EBITDA | −$338.9M | −$394.9M | −$310.5M | −$337.7M | −$223.2M | −$345.5M | $723.6M | −$408.6M |
| Net income | −$346.0M | −$411.5M | −$327.4M | $1.60B | −$231.8M | −$352.1M | $673.7M | −$412.8M |
| Net margin | -366.6% | -349.0% | — | — | -1627.8% | -1312.6% | 1845.9% | -764.0% |
| EPS (diluted) | -6.03 | -6.61 | -4.74 | -6.36 | -4.23 | -6.33 | 11.64 | -7.12 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $122M | $-6.23 | $-7.18–$-5.46 | 8 |
| 2027 | $257M | $-4.77 | $-5.74–$-3.61 | 8 |
| 2028 | $392M | $-3.45 | $-4.77–$-1.40 | 8 |
| 2029 | $531M | $-1.91 | $-2.61–$-1.14 | 6 |
Forward consensus · source: Financial Modeling Prep
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
www.agios.comNo one on the platform currently holds AGIO.
No tracked institution reports a position in AGIO as of their last filing.
No one on the platform has traded AGIO yet.
| $2.2B |
| — |
| GLPGGalapagos N.V. | $27.98 | +1.71% | $1.8B | — |
| IBRXImmunityBio, Inc. | $8.76 | -0.17% | $9.2B | — |
Source: Financial Modeling Prep · peers by sector/industry
Trading at 56.9× sales vs its 56.9× historical median P/S.
Fair value ≈ $37.11 · price $37.11 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$AGIO GEE is siht bag Goldman Sachs , reaching for inventory to sell ???? Afterall, they are SHORT the stock, have been since 2022, …WHY ??? Schenkien lied to them, and just plain fcuked them in 2015 !!!
View on StockTwits ↗$AGIO Agios Pharmaceuticals (Nasdaq: $AGIO): From Mitapivat Launch Story to Broader Rare-Disease Hematology Platform https://www.merlintrader.com/agios-pharmaceuticals-stock-hub/
View on StockTwits ↗$AGIO (+1.6% pre) Sickle cell patients needed fewer transfusions with Agios pill in Phase 3 https://ooc.bz/l/105119
View on StockTwits ↗$AGIO Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease "Mitapivat demonstrated statistically significant improvement in hemoglobin response compared with placebo, with rapid onset and durable effects Company to host investor conference call and webcast today at 9:00 a.m. ET"
View on StockTwits ↗https://marketbeat.com/a/8713294/ $AGIO Agios Pharmaceuticals Touts Mitapivat Gains Despite Sickle Cell Pain Miss
View on StockTwits ↗$AGIO EHA 2026 data dump — the numbers that mattered: Thalassemia (AQVESME, already approved) • ENERGIZE OLE: Hb response climbed 42.3% → ~60% (72/121) with continued treatment • ~1/3 of prior non-responders converted to responders over time • Duration of response more than doubled: 17.9 → 43.6 wks • High-baseline subgroup (≥9.5 g/dL): 38.9% (7/18) response vs 0% placebo; FACIT-Fatigue +5.1 vs +0.8 • SATISFY (membranopathies): 48% (10/21) Hb response, +1.1 g/dL, hemolysis + iron burden down SCD (mitapivat, RISE UP Ph3 plenary — sNDA filed) • Hb response 40.6% vs 2.9% placebo, p<0.0001 — maintained through Wk52 • SCPC pain-crisis co-primary MISSED: 14% RR, p=0.12 • ITT PROMIS-Fatigue also missed (p=0.71) • Responders saw 26% fewer crises / 34% fewer hospitalizations / 53% fewer ER visits • Post-hoc transfusion: 41% fewer pts transfused, 56% fewer units • Safety clean — no treatment-related deaths, >1,300 patient-yrs across 3 anemias Other • AG-236 (PV): Ph1 HV done, advancing to late-stage — every-6-mo dosing potential with best in class potential in a $1 billion TAM. • AQVESME launch: 242 scripts as of 3/31 with new data presented that more than doubles their persciber bass with NTD patients. Hb endpoints carried both programs; the clinical co-primary in SCD didn’t, and a case was presented to seek approval on endpoints presented today that showed statistical significance and improved biomarker with longer duration . NFAD / DYOR.
View on StockTwits ↗$AGIO Ah the churn came down You pathetic misfits get your stock sold ? Quarter end , like clock work Neither of you will ever be : Elon Musk or Mark Ales John Maraganore David meeker Richard Barry Alex Karp You are just pathetic public money welfare recipients
View on StockTwits ↗$AGIO end of the quarter , Morgan Stanley aiding the losers by churning the stock higher for the slobs , Fouse and Goff , Milanova and Jones , to cash in on their options !! Never have they created value on their own, mere false value for their private benefit..WELFARE CASES , the whole mgmt team
View on StockTwits ↗$AGIO 2M shares on a NEUTRAL from JPM Is SELL, SELL, SELL volume This pos only does 800K on a non event day This was a SELL EVENT Hahahaha GOFF the GOOF BALL is under water after 4 years here, on his hire on options of 29.38 FOUSE Is under water on her 40K shares at $30 in 2019 , 7 years later These two misfits just can’t create value !!! Never mind useless Milanova with no marketing strategy Sarah G . With constant lab fcuk ups and oh gee , it didn’t work Jones contributes nothing, just like Krishnan !!! Chris Bowden where are you when these misfits need an overhaul ???
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.